A Facile and Promising Delivery Platform for siRNA to Solid Tumors

Area of Science:

• Biotechnology
• Molecular Biology
• Cancer Research

Background:

• Small interfering RNA (siRNA) has potential for treating diseases, but systemic delivery for extrahepatic targets remains challenging.
• Current FDA-approved siRNA therapies primarily target the liver, often using complex carriers for extrahepatic applications.
• The complexity of existing carriers hinders the widespread clinical use of siRNA for treating diseases outside the liver.

Purpose of the Study:

• To develop and evaluate a simple, effective linear peptide carrier for systemic siRNA delivery to extrahepatic tumors.
• To assess the efficacy of histidine-lysine (HK) peptide-siRNA polyplexes in silencing tumor-specific gene expression in vivo.
• To investigate the impact of brief bath sonication on the silencing efficiency of HK siRNA polyplexes.

Main Methods:

• Systemic intravenous injection of linear histidine-lysine (HK) peptide-siRNA polyplexes in a mouse model with MDA-MB-435 tumors.
• Assessment of gene silencing by measuring luciferase activity in tumors.
• Screening of various linear peptides containing the -KHHK- sequence for siRNA delivery efficacy.
• Confirmation of silencing in a second tumor model (MDA-MB-231 xenografts) and evaluation of oncogene (Raf-1) reduction.

Main Results:

• Linear HK peptide-siRNA polyplexes effectively silenced luciferase expression in MDA-MB-435 tumors.
• Brief bath sonication significantly enhanced both in vitro and in vivo silencing.
• Screening identified several linear peptides with the -KHHK- sequence that silenced up to 80% of the tumor luciferase marker.
• Silencing was confirmed in a second tumor model, with significant reduction in both luciferase activity and Raf-1 oncogene expression.

Conclusions:

• Simple, easily synthesized linear HK peptides are effective carriers for systemic siRNA delivery to extrahepatic tumors.
• These HK siRNA polyplexes demonstrate significant gene silencing capabilities, including oncogene reduction, in preclinical models.
• The developed HK peptide carriers show great promise for future clinical applications in treating extrahepatic diseases like cancer.